Adipotide

What is Adipotide?

AdipoTide is an experimental weight loss drug that was being studied to help people with obesity lose weight. It works very differently from other weight loss medications. Instead of reducing your appetite or blocking fat absorption, adipotide was designed to destroy the blood vessels that feed fat tissue. When these blood vessels are destroyed, the fat cells they supply die off, leading to weight loss. However, this medication is not approved by the FDA and is not available for legal prescription use.

Why Was Development Stopped?

Clinical trials of adipotide were stopped early because the drug caused serious kidney damage in people who took it. The same mechanism that destroys blood vessels in fat tissue also affected blood vessels in the kidneys, causing potentially permanent kidney injury. Many people in the studies developed protein in their urine and elevated kidney function tests, which are signs of kidney damage. Because of these serious safety problems, the drug company stopped all research on adipotide. The risks were considered too great compared to the potential benefits for weight loss.

Important Safety Warning

You may see adipotide advertised online or available through unregulated sources, sometimes marketed as a "research chemical" or "peptide therapy" for weight loss. Do not use this drug. It is not approved for human use and can cause serious, potentially permanent kidney damage. There are no safe dosing guidelines, and using adipotide obtained outside of legitimate medical research could result in kidney failure requiring dialysis or transplant. If you are struggling with obesity, talk to your healthcare provider about FDA-approved weight loss medications and other safe, effective treatment options.

What Should You Know?

If you encounter adipotide or someone offers it to you for weight loss, understand that this is an experimental drug that failed safety testing. The kidney damage it causes can be irreversible, meaning your kidneys may never fully recover. Symptoms of kidney problems include swelling in your legs or feet, decreased urination, fatigue, nausea, and confusion. If you have used adipotide and experience any of these symptoms, seek immediate medical attention and tell your healthcare provider exactly what you took. There are many safe, FDA-approved options for weight loss including medications like semaglutide, liraglutide, and phentermine/topiramate, as well as lifestyle modifications and bariatric surgery for appropriate candidates. Always discuss weight loss treatments with a qualified healthcare provider who can help you find safe and effective options.

Adipotide, also known as FTPP (fat-targeted proapoptotic peptide) or formerly as prohibitin-targeting peptide 1, represents a novel approach to obesity treatment through targeted destruction of adipose tissue vasculature. Developed initially by researchers at the University of Texas MD Anderson Cancer Center and later advanced by Arrowhead Pharmaceuticals (formerly Arrowhead Research Corporation), adipotide was designed based on the principle that destroying the blood supply to fat tissue would result in fat loss, similar to anti-angiogenic approaches used in cancer therapy.

The compound emerged from research into prohibitin as a vascular targeting marker in the early 2000s. Preclinical studies in obese rhesus monkeys demonstrated significant weight loss and improvements in insulin sensitivity, generating substantial interest in the compound's therapeutic potential. These promising animal studies led to human clinical trials, with Phase I studies initiated to evaluate safety, tolerability, and preliminary efficacy in obese human subjects.

However, clinical development of adipotide has been discontinued due to significant safety concerns that emerged during human trials. The most serious adverse effect observed was renal toxicity, manifesting as proteinuria, elevated creatinine levels, and evidence of glomerular injury. These renal effects were attributed to prohibitin expression in kidney vasculature, leading to unintended targeting of renal blood vessels. Additional concerns included potential effects on wound healing and the theoretical risk of targeting other vascular beds where prohibitin is expressed.

Despite its discontinuation for clinical use, adipotide remains of scientific interest as a proof-of-concept for vascular-targeted obesity therapy. The compound demonstrated that selective destruction of adipose vasculature could produce weight loss in humans, validating the underlying biological principle. Current research focuses on developing next-generation compounds with improved selectivity profiles that might avoid the renal toxicity observed with adipotide while retaining efficacy against adipose tissue.

AdipoTide is not FDA-approved and is not available for prescription use. Any use of this compound outside of approved clinical trials is considered experimental and potentially dangerous. The compound is sometimes discussed in research contexts and unfortunately has appeared in unregulated markets, where its use poses serious health risks due to the documented potential for kidney damage and other adverse effects.

Adipotide functions as a chimeric peptide that selectively targets and destroys the blood supply to white adipose tissue through a dual-mechanism approach. The compound consists of two functional domains: a homing peptide sequence (CKGGRAKDC) that binds to prohibitin receptors expressed on the surface of endothelial cells in adipose tissue vasculature, and a pro-apoptotic peptide domain (D[KLAKLAK]2) that induces programmed cell death once internalized.

The prohibitin receptor is preferentially expressed on endothelial cells within white adipose tissue and certain tumor vasculature, providing tissue selectivity. Upon binding to prohibitin, adipotide undergoes receptor-mediated endocytosis into the target endothelial cells. Once internalized, the pro-apoptotic domain disrupts mitochondrial membranes by forming pores, leading to cytochrome c release, caspase activation, and subsequent apoptosis of the vascular endothelial cells.

The destruction of adipose tissue vasculature results in localized ischemia and subsequent apoptosis of adipocytes that depend on this blood supply for oxygen and nutrients. This mechanism differs fundamentally from traditional weight loss medications that target appetite, metabolism, or nutrient absorption. The targeted vascular destruction leads to reduction in adipose tissue mass without direct effects on adipocytes themselves.

The selectivity for white adipose tissue over brown adipose tissue and other vascular beds is attributed to the differential expression patterns of prohibitin receptors. However, prohibitin expression is not entirely specific to adipose vasculature, which may contribute to off-target effects observed in clinical studies, particularly affecting renal vasculature where prohibitin is also expressed.

Important Notice

AdipoTide is not FDA-approved and has no established dosing guidelines for clinical use. The information below is provided for educational purposes only, based on investigational protocols from discontinued clinical trials. Adipotide should not be used outside of approved research settings.

Investigational Dosing (Historical Reference Only)

Based on discontinued Phase I clinical trials, the following dosing ranges were explored:

Subcutaneous Administration

Preclinical Effective Doses (Rhesus Monkeys)

• Effective dose range: 0.25-1.0 mg/kg subcutaneously every other day

• Duration: 4-8 weeks for maximal effect

• Weight loss observed: 8-11% of baseline body weight

Administration Guidelines (Investigational)

Route: Subcutaneous injection only

Preparation: Reconstitution with sterile water for injection or bacteriostatic saline (specific protocols varied by trial)

Injection sites: Abdomen, thigh, or upper arm with site rotation to minimize local reactions

Storage: Lyophilized powder stored at 2-8°C; reconstituted solution used within 24 hours or as specified by protocol

Dose Adjustments

Renal Impairment

Contraindicated in any degree of renal impairment due to nephrotoxicity risk. Clinical trials excluded patients with:

• Baseline creatinine >1.2 mg/dL

• Proteinuria >150 mg/day

• eGFR <90 mL/min/1.73m²

Hepatic Impairment

No specific dosing adjustments studied; use was generally avoided in hepatic impairment

Geriatric Patients

No data available; elderly patients were typically excluded from trials

Pediatric Patients

Not studied; contraindicated in patients <18 years

Monitoring Requirements (From Investigational Protocols)

If adipotide were to be used in research settings, intensive monitoring would include:

• Baseline: Complete metabolic panel, urinalysis with protein quantification, CBC, renal ultrasound

• Weekly: Serum creatinine, BUN, urinalysis with protein/creatinine ratio

• Bi-weekly: Complete metabolic panel, liver function tests

• Monthly: Comprehensive metabolic assessment, body composition analysis

• Discontinuation criteria: Proteinuria >500 mg/day, creatinine increase >0.3 mg/dL from baseline, or any signs of acute kidney injury

Critical Safety Note

The dosing information above is provided solely for educational and historical reference. Adipotide demonstrated unacceptable toxicity in human trials and should not be administered outside of properly approved and monitored research protocols with full ethical oversight and informed consent. Any use of this compound obtained through unregulated sources poses serious health risks, particularly irreversible kidney damage.

Clinical evidence for adipotide is limited to preclinical studies and early-phase human trials, as the compound never progressed beyond Phase I/II development. The most substantial preclinical data comes from studies in diet-induced obese rhesus monkeys, published in Science Translational Medicine in 2011. In this pivotal study, obese monkeys treated with adipotide at doses of 0.25-1.0 mg/kg administered subcutaneously every other day for 4 weeks demonstrated significant weight loss averaging 11% of baseline body weight, compared to minimal changes in control animals. Importantly, the weight loss was accompanied by improvements in insulin sensitivity and reductions in circulating triglycerides and leptin levels, suggesting metabolic benefits beyond simple weight reduction.

Histological examination of adipose tissue from treated animals revealed evidence of vascular disruption with endothelial cell apoptosis, followed by adipocyte death and macrophage infiltration consistent with the proposed mechanism of action. Imaging studies using MRI confirmed selective reduction in white adipose tissue mass, particularly visceral fat depots. However, even in these preclinical studies, concerns emerged regarding renal effects, with some animals showing transient increases in urinary protein excretion and histological evidence of glomerular injury at higher doses.

Human clinical trials of adipotide were initiated but never completed or fully published in peer-reviewed literature. Available information from conference presentations and regulatory documents indicates that Phase I studies enrolled small numbers of obese subjects (BMI >30 kg/m²) who received escalating doses of subcutaneous adipotide. Preliminary efficacy data suggested weight loss in the range of 5-10% over 4-8 weeks in some subjects, with dose-dependent effects. However, the trials were terminated early due to safety signals, particularly dose-limiting renal toxicity manifesting as proteinuria (protein excretion >1 g/day in some subjects) and elevated serum creatinine levels.

Renal biopsies performed in some affected subjects revealed glomerular endothelial injury and focal segmental glomerulosclerosis patterns, consistent with vascular targeting effects in the kidney. These findings suggested that prohibitin expression in renal vasculature led to unintended kidney damage through the same mechanism intended to destroy adipose vasculature. Additional adverse effects reported included injection site reactions, transient elevations in liver enzymes, and concerns about impaired wound healing in some subjects. The unfavorable risk-benefit profile led to discontinuation of clinical development by Arrowhead Pharmaceuticals.

No comparative effectiveness studies were conducted comparing adipotide to approved weight loss medications or bariatric surgery. The compound never reached the stage of large-scale randomized controlled trials that would be required for regulatory approval. Current clinical evidence is insufficient to support any therapeutic use of adipotide, and the documented safety concerns, particularly nephrotoxicity, represent significant barriers to further development without substantial modification of the compound structure to improve selectivity.

Absolute Contraindications

AdipoTide is not approved for any clinical use. If it were to be considered in research settings, absolute contraindications would include:

• Any pre-existing renal disease or impairment (eGFR <90 mL/min/1.73m²)

• Baseline proteinuria (>150 mg/day)

• History of glomerulonephritis or nephrotic syndrome

• Pregnancy or breastfeeding

• Active malignancy or history of cancer within 5 years

• Uncontrolled hypertension (>140/90 mmHg)

• Recent surgery or planned surgical procedures within 3 months

• Known hypersensitivity to peptide therapeutics

• Age <18 years or >65 years

• Concurrent use of nephrotoxic medications

Relative Contraindications and Warnings

• Diabetes mellitus with any evidence of diabetic nephropathy

• Cardiovascular disease, particularly peripheral vascular disease

• Autoimmune disorders affecting vasculature

• Bleeding disorders or anticoagulant therapy

• Hepatic impairment (any degree)

• BMI <30 kg/m² (insufficient risk-benefit ratio)

• History of wound healing complications

• Concurrent use of NSAIDs, ACE inhibitors, or ARBs

Serious Adverse Effects

Nephrotoxicity (Most Significant)

Incidence: Dose-dependent; observed in significant proportion of subjects at therapeutic doses

Manifestations:

• Proteinuria (ranging from mild to nephrotic range >3 g/day)

• Elevated serum creatinine and BUN

• Reduced glomerular filtration rate

• Acute kidney injury in severe cases

• Histological findings: glomerular endothelial injury, focal segmental glomerulosclerosis

• Potential for irreversible renal damage

Mechanism: Prohibitin expression in renal vasculature leads to unintended targeting and destruction of kidney blood vessels

Management: Immediate discontinuation; supportive care; nephrology consultation; some cases required temporary dialysis

Vascular and Cardiovascular Effects

• Impaired wound healing due to anti-angiogenic effects

• Theoretical risk of ischemic events in other vascular beds

• Hypertension (mechanism unclear, possibly related to renal effects)

• Peripheral edema

Hepatotoxicity

• Transient elevations in ALT/AST (typically <3x upper limit of normal)

• Mechanism unclear; generally reversible upon discontinuation

Common Adverse Effects

Based on limited clinical trial data:

• Injection site reactions (50-70% of subjects): pain, erythema, induration, bruising

• Fatigue (30-40%): possibly related to metabolic changes from rapid weight loss

• Nausea (20-30%): mechanism unclear

• Headache (15-25%)

• Dizziness (10-20%)

• Gastrointestinal disturbances: diarrhea, abdominal discomfort (10-15%)

Monitoring Parameters

Essential Monitoring (If Used in Research Settings)

Renal Function (Primary Safety Concern):

• Serum creatinine and BUN: baseline, then weekly

• Urinalysis with microscopy: baseline, then weekly

• Urine protein/creatinine ratio: baseline, then weekly

• eGFR calculation: baseline, then weekly

• Consider renal ultrasound at baseline and if abnormalities develop

Metabolic Parameters:

• Comprehensive metabolic panel: baseline, then bi-weekly

• Liver function tests: baseline, then bi-weekly

• Lipid panel: baseline, monthly

• Hemoglobin A1c (if diabetic): baseline, monthly

Cardiovascular:

• Blood pressure: each visit

• Heart rate: each visit

• ECG: baseline and as clinically indicated

Body Composition:

• Weight: weekly

• Body composition analysis (DEXA or bioimpedance): baseline, monthly

Safety Assessments:

• Complete blood count: baseline, monthly

• Coagulation parameters if on anticoagulants: baseline, bi-weekly

• Wound assessment if any injuries occur

Special Populations

Pregnancy and Lactation

Pregnancy Category: Not assigned (never approved); would likely be Category X

Risk: Theoretical risks include:

• Disruption of placental vasculature

• Fetal growth restriction

• Teratogenic potential unknown

• Absolutely contraindicated in pregnancy

Lactation: Unknown if excreted in breast milk; contraindicated due to potential effects on infant and lack of safety data

Contraception: Women of childbearing potential would require reliable contraception during treatment and for at least 3 months after discontinuation

Pediatric Population

No data in patients <18 years; contraindicated due to:

• Unknown effects on growth and development

• Potential vascular effects during critical developmental periods

• Lack of safety and efficacy data

Geriatric Population

No adequate data in patients >65 years; concerns include:

• Higher baseline prevalence of renal impairment

• Increased cardiovascular risk

• Impaired wound healing capacity

• Polypharmacy and drug interaction risks

• Generally excluded from investigational trials

Renal Impairment

Contraindicated at any level of renal impairment due to:

• Primary toxicity target is renal vasculature

• Increased risk of acute kidney injury

• Potential for irreversible renal damage

• Altered pharmacokinetics with reduced clearance

Hepatic Impairment

Limited data; generally avoided in clinical trials due to:

• Observed hepatic enzyme elevations

• Unknown effects on peptide metabolism

• Potential for exacerbation of underlying liver disease

Black Box Warning Equivalent

If adipotide were approved, it would warrant the strongest safety warnings:

NEPHROTOXICITY: Adipotide causes dose-dependent kidney damage that may be irreversible. Proteinuria, elevated creatinine, and acute kidney injury have been observed in clinical trials. Renal function must be normal at baseline and monitored intensively during treatment. Discontinue immediately if any signs of renal impairment develop. Use only when potential benefits clearly outweigh serious risks.

Overdose

No specific antidote exists. Overdose would likely result in:

• Severe nephrotoxicity with acute kidney injury

• Potential multi-organ vascular effects

• Management: discontinuation, supportive care, nephrology consultation, possible dialysis

• Hemodialysis may remove some peptide but would not reverse vascular damage already induced

Critical Safety Summary

AdipoTide demonstrated unacceptable toxicity in human trials, primarily severe nephrotoxicity, leading to termination of clinical development. The compound should not be used outside of properly approved research protocols. Any use obtained through unregulated sources poses serious health risks including potentially irreversible kidney damage. Healthcare providers should be aware that this compound may appear in unregulated markets and counsel patients about the serious dangers of its use.

Pharmacokinetics

The pharmacokinetic profile of adipotide has been characterized primarily through preclinical studies and limited Phase I human data. As a peptide compound with a molecular weight of approximately 2.3 kDa, adipotide exhibits pharmacokinetic properties typical of small therapeutic peptides. Following subcutaneous administration, the compound demonstrates relatively rapid absorption with peak plasma concentrations (Tmax) occurring within 1-3 hours. The absolute bioavailability via subcutaneous injection is estimated at 40-60%, which is consistent with other peptide therapeutics of similar size.

The distribution of adipotide is characterized by preferential accumulation in adipose tissue vasculature due to its prohibitin-targeting domain. The volume of distribution is relatively limited, suggesting minimal penetration into deep tissue compartments beyond the vascular space and targeted adipose tissue. Plasma protein binding has not been extensively characterized but is expected to be moderate given the peptide nature of the compound. The elimination half-life ranges from 2-4 hours in human subjects, necessitating frequent dosing to maintain therapeutic concentrations.

Metabolism of adipotide occurs primarily through proteolytic degradation by peptidases in plasma and tissues. The compound is broken down into constituent amino acids through standard peptide catabolism pathways. No specific cytochrome P450 metabolism occurs due to the peptide structure. Elimination occurs through both renal filtration of intact peptide and metabolites, and through cellular uptake and degradation in target tissues. Renal clearance represents a significant elimination pathway, which may contribute to the observed nephrotoxicity as the compound or its fragments interact with renal vasculature.

Pharmacodynamics

The pharmacodynamic effects of adipotide are characterized by dose-dependent reduction in adipose tissue mass through vascular targeting. In preclinical studies, effects on body weight became apparent within 1-2 weeks of treatment initiation, with maximal effects observed after 4-8 weeks of continuous therapy. The relationship between plasma concentration and therapeutic effect is complex, as the compound's activity depends on tissue accumulation and endothelial cell internalization rather than simple plasma exposure.

Biomarkers of adipotide activity include reductions in body weight, decreased adipose tissue volume on imaging studies, and improvements in metabolic parameters such as insulin sensitivity and lipid profiles. However, these beneficial effects are accompanied by biomarkers of toxicity, particularly urinary protein excretion and serum creatinine elevation, which reflect the compound's effects on renal vasculature. The therapeutic window appears narrow, with doses required for efficacy approaching those that produce significant adverse effects.

Drug Interactions

Formal drug-drug interaction studies with adipotide are limited due to the early termination of clinical development. As a peptide that does not undergo cytochrome P450 metabolism, traditional pharmacokinetic drug interactions are unlikely. However, potential pharmacodynamic interactions exist with medications affecting renal function, including NSAIDs, ACE inhibitors, ARBs, and diuretics, which could theoretically exacerbate nephrotoxicity. Anticoagulants and antiplatelet agents might interact with adipotide's vascular effects, though this has not been systematically studied. Concomitant use with other weight loss medications or agents affecting angiogenesis would require careful consideration due to potential additive effects on vascular integrity.